Health-related quality of life assessments in osteoarthritis during NSAID treatment

Pharmacy World and Science

Volumn 18, Issue 4, 1996, Pages 130-136

  De Bock, G H ^a   Hermans, J ^a   Van Marwijk, H W J ^a   Kaptein, A A ^a   Mulder, J D ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

activities of daily living; nabumetone; piroxicam, osteoarthritis; randomized controlled trials; Sickness Impact Profile

Indexed keywords

NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MALE; NETHERLANDS; OSTEOARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0029776756     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf00717728     Document Type: Article

References (41)

1. Scott JC, Hochberg MC. Osteoarthritis I: epidemiology. Md State Med J 1984;33:712-6.
2. Pincus T, Mitchell JM, Burkhauser RV. Substantial work disability and earnings losses in individuals less than age 65 with osteoarthritis: comparisons with rheumatoid arthritis. J Clin Epidemiol 1989;42:449-57.
3. Yelin E, Lubeck D, Holman H, Epstein W. The impact of rheumatoid arthritis and osteoarthritis: the activities of patients with rheumatoid arthritis and osteoarthritis compared to controls. J Rheumatol 1987;14:710-7.
4. Lubeck DP, Yelin EH. A question of value: measuring the impact of chronic disease. Milbank Quart 1988;66:444-64.
5. Leigh TJ, Hindmarch I, Bird HA, Wright V. Comparison of sleep in osteoarthritic patients and age and sex matched healthy controls. Ann Rheum Dis 1988;47:40-2.
6. Davis MA, Ettinger WH, Neuhaus JM, Mallon KP. Knee osteoarthritis and physical functioning: evidence from the NHANES I epidemiologic follow-up study. J Rheumatol 1991;18:591-8.
7. De Bock GH, Kaptein AA, Touw-Otten FWMM, Mulder JD. Health-related quality of life in patients with osteoarthritis in a family practice setting. Arthritis Care Res 1995;8:88-93.
8. Wood PHN, Badley E. Rheumatic disorders. In: Epidemiology of diseases. Miller DL, Farmer RDT (eds). Oxford: Blackwell Scientific Publication, 1982:333-46.
9. Voorn TB. Chronic diseases in general practice [Chronische ziekten in de huisartspraktijk]. Utrecht: Wetenschappelijke Uitgeverij Bunge, 1983.
10. De Bock GH, Kaptein AA, Mulder JD. Dutch general practitioner's management of patients with distal osteoarthritic symptoms. Scand J Prim Health Care 1992;10:42-6.
11. Steele K, Mills KA, Gilliland AEW, Irwin WG, Taggart A. Repeat prescribing of non-steroidal anti-inflammatory drugs excluding aspirin: how careful are we? Brit Med J 1987; 295: 962-4.
12. Committee on the Safety of Medicines. CSM update: non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions 1. Brit Med J 1986;292:614.
13. Vermeulen HN, Stricker BHCh, De Koning GHP, Porsius AJ. A comparison of reported suspected adverse drug reactions between a regional centre and a national centre [Een vergelijking van de meldingen van vermoedelijke bijwerkingen bij een regionaal en een landelijk meldingssysteem]. Pharm Weekbl 1990;125:931-6.
14. Roth SH. Endoscopy controlled study of the safety of nabumetone compared with naproxen in arthritis therapy. Am J Med 1987;30(4B):25-30.
15. Greb WH, Von Schrader HW, Cerlek S, Dominis M, Hauptmann E, Zenic N. Endoscopic studies of nabumetone in patients with rheumatoid arthritis: a comparative endoscopic and histologic evaluation. Am J Med 1987;30(4B):19-24.
16. Lussie A, Le Bel E. Radiochromium (chromium-51) evaluation of gastrointestinal blood loss associated with placebo, aspirin, and nabumetone. Am J Med 1987;30(4B):15-8.
17. Friedel HA, Langtry HD, Buckley MM. Nabumetone: a reappraisal of its pharmacology and therapeutic use in rheumatic diseases. Drugs 1993;45:131-56.
18. Roth SH. Nabumetone: a new NSAID for rheumatoid arthritis and osteoarthritis. Orthop Rev 1992;21:223-7.
19. Verbruggen LA, Pintens H. Efficacy and safety of nabumetone in long-term treatment of osteoarthritis. Int J Tissue React 1984;6:339-42.
20. Verbruggen LA, Cytryn E, Pintens H. Double-blind cross-over study of nabumetone versus naproxen in the treatment of osteoarthritis. J Int Med Res 1982;10:214-8.
21. De Bock GH, Hermans J, Mulder JD. Randomized double-blind study of nabumetone and piroxicam in the treatment of osteoarthritis in Dutch general practice: efficacy and tolerability. Pharm World Sci 1993;15:132-8.
22. The Classification Committee of WONCA (World Organization of National Colleges, Academies, and Academic Associations of General Practitioners/Family Physicians) in collaboration with the World Health Organization. ICHPPC-2-Defined (International Classification of Health Problems in Primary Care). Oxford: Oxford University Press, 1983.
23. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949;140:659-62.
24. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and revision of a health status measure. Med Care 1981;19:787-805.
25. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. J Am Med Assoc 1963;185:914-9.
26. Katz S, Akpom CA. Index of ADL. Med Care 1976;14:116-8.
27. Katz S, Akpom CA. A measure of primary sociobiological functions. Int J Health Serv 1976;6:493-508.
28. Culpepper L. Symptoms, measures of the mind. In: Tools of primary care research. Stewart M, Tudiver F, Bass MJ, Dunn EV, Norton PG (ed). Research methods for primary care: 2. Newbury Park: SAGE publications 1992:113-23.
29. Hunt S, McEwen J, McKenna S. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract 1985;35:185-8.
30. Fitzpatrick R, Fletcher A, Gore S, Jones D, Spiegelhalter D, Cox D. Quality of life measures in health care. I: Applications and issues in assessment. Brit Med J 1992;305:1074-7.
31. Wilkin D, Hallam L, Doggett M-A. Measures of need and outcome for primary health care. Oxford: Oxford University Press, 1993 [revised edition].
32. The SIP (Dutch version) is available from Department of General Practice, University of Utrecht, The Netherlands. Tel-31-30-2538188.
33. Luttik A, Jacobs HM, De Witte LP. The Sickness-Impact-Profile. Utrecht: Department of Family Medicine, University of Utrecht, 1987.
34. Jacobs HM, Luttik A, Touw-Otten FWMM, De Melker RA. The 'Sickness Impact Profile': results of a validation study of the Dutch version [De 'Sickness Impact Profile; resultaten van een valideringsonderzoek van de Nederlandse versie]. Ned Tijdschr Geneeskd 1990;134:1950-4.
35. De Bruin AF, De Witte LP, Stevens F, Diederiks JPM. Sickness Impact Profile: the state of the art of a generic functional status measure. Soc Sci Med 1992;35:1003-14.
36. The ADL (Dutch version) is available from Department of Psychiatry, Leiden University, The Netherlands. Tel-31-71-5275237.
37. Kaptein AA, Dekker FW, Dekhuijzen PNR, Wagenaar JPM, Janssen PJ. The value of the 12-minute walking test in patients with chronic obstructive pulmonary disease. II. Walking in the laboratory and walking in daily life [De 12-minuten-looptest bij patiënten met een chronische uitademingsstoornis. II. Lopen in net laboratorium en lopen in het leven]. Ned Tijdschr Geneeskd 1987;131:1717-21.
38. Huskisson EC. Measurement of pain. Lancet 1974; ii: 1127-31.
39. Cohen J. Statistical power analysis for the behavioral sciences. New York: Lawrence Erlbaum Associates, 1977.
40. Deyo RA. Measuring the quality of life of patients with rheumatoid arthritis. In: Quality of life assessment: key issues in the 1990s. Walker SR, Rosser RM (Eds). Lancaster, UK: Kluwer Academic Publishers 1993.
41. De Bock GH, Van Marwijk HWJ, Kaptein AA, Mulder JD. Osteoarthritis pain assessment in general practice. Arthritis Care Res 1994;7:40-5.